文献速递妇科产科

BRCA1/2携带者输卵管切除联合延迟卵巢切除与输卵管卵巢切除对比:前瞻性偏好试验三年结局

Salpingectomy With Delayed Oophorectomy Versus Salpingo-Oophorectomy in BRCA1/2 Carriers: Three-Year Outcomes of a Prospective Preference Trial.
PubMed 文献 · BJOG · 2025-01-17

这项在荷兰十三家医院开展的多中心前瞻性偏好试验,比较BRCA1/2致病性变异携带者接受降低风险输卵管切除(RRS)与降低风险输卵管卵巢切除(RRSO)术后3年内绝经相关生活质量。至2023年4月,410例接受RRS、160例接受RRSO。RRSO未用激素替代治疗(HRT)者术后3年Greene绝经量表(GCS)评分较基线升高比RRS组多4.3分(95%CI 2.1-6.5;p<0.001),术后1年时差异最明显。

要点

  • RRSO未用HRT者术后3年GCS评分升高较RRS组多4.3分(95%CI 2.1-6.5;p<0.001)。
  • RRSO用HRT者术后3年GCS评分升高较RRS组多2.4分(95%CI 0.8-3.9;p=0.002)。
  • 两组差异在术后1年内最明显。

核心结论

  • 在这项多中心偏好试验中,RRS术后绝经相关生活质量优于RRSO,即使RRSO术后使用HRT亦然。
  • 两组差异在术后1年内最明显。

研究设计与样本

  • 研究为前瞻性偏好试验(TUBA研究),在荷兰十三家医院开展的多中心研究。
  • 纳入年龄25-40岁(BRCA1)或25-45岁(BRCA2)、绝经前、无未来生育意愿且无当前恶性肿瘤(或治疗)的BRCA1/2致病性变异携带者。
  • 治疗分配基于患者偏好:RRS从25岁开始,延迟卵巢切除最大年龄45岁(BRCA1)或50岁(BRCA2);或RRSO在35-40岁(BRCA1)或40-45岁(BRCA2)之间。
  • RRSO后如无禁忌推荐HRT。
  • 数据采集于术前及术后3个月、1年、3年。

主要发现

  • RRSO未用HRT者术后3年GCS评分较基线升高比RRS组多4.3分(95%CI 2.1-6.5;p<0.001)。
  • RRSO未用HRT者与RRS组GCS评分较基线升高的差异在术后3个月为7.9分(95%CI 5.9-9.8),术后12个月为8.5分(95%CI 6.5-10.5)。
  • 术后使用HRT者中,RRSO组GCS评分较基线升高比RRS组多2.4分(95%CI 0.8-3.9;p=0.002)。

关键数值与推荐

  • 主要比较RRS组与RRSO未用HRT组的绝经相关生活质量,采用Greene绝经量表(GCS)评估,评分越高绝经症状越多。
  • 次要比较RRS组与RRSO术后使用HRT组的GCS评分。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare menopause-related quality of life (QoL) after risk-reducing salpingectomy (RRS) versus risk-reducing salpingo-oophorectomy (RRSO) until 3 years of post-surgery. DESIGN: A prospective study (TUBA study) with treatment allocation based on patients' preference. Data were collected pre-surgery and at 3 months, 1 and 3 years of post-surgery. SETTING: Multicentre prospective preference trial in thirteen hospitals in the Netherlands. POPULATION: BRCA1/2 pathogenic variant (PV) carriers aged 25-40 (BRCA1) or 25-45 (BRCA2), who were premenopausal, without a future child wish and without current (treatment for) malignancy. METHODS: Treatment allocation was based on patients' preference: either RRS from the age of 25 years with delayed oophorectomy at the maximum age of 45 (BRCA1) or 50 (BRCA2), or RRSO between the ages of 35-40 (BRCA1) or 40-45 (BRCA2). After RRSO, hormone replacement therapy (HRT) was recommended, if not contraindicated. Primarily, menopause-related QoL as measured with the Greene Climacteric Scale (GCS) was compared between the RRS and RRSO without HRT group. Secondarily, GSC-scores of the RRS group were compared with the scores of the RRSO with HRT after surgery group. A higher GSC-score reflects more climacteric symptoms. RESULTS: Until April 2023, 410 participants had undergone RRS and 160 RRSO. The BRCA1/BRCA2 proportions were 51.4%/48.6%. The mean age at surgery (SD) was 37.9 (3.5) years. Participants 3 years after RRSO without HRT had a 4.3 (95% CI 2.1-6.5; p < 0.001) point higher increase in GCS-score from baseline compared to those after RRS, while the difference was 7.9 (95% CI 5.9-9.8) and 8.5 (95% CI 6.5-10.5) points at 3 and 12 months, respectively. Among participants with HRT after surgery, the RRSO group had a 2.4 (95% CI 0.8-3.9; p = 0.002) point higher increase in GCS-score from baseline compared to the RRS group. CONCLUSIONS: In this multicentre preference trial, menopause-related QoL was better after RRS than after RRSO, even with HRT after RRSO. Differences between arms were most pronounced until one-year post-surgery.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Van Bommel MHD, Steenbeek MP, Inthout J, et al. Salpingectomy With Delayed Oophorectomy Versus Salpingo-Oophorectomy in BRCA1/2 Carriers: Three-Year Outcomes of a Prospective Preference Trial. BJOG. 2025. PMID: 39823150. doi:10.1111/1471-0528.18075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。